Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies

Riccardo Lencioni

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The treatment of hepatocellular carcinoma (HCC) is rapidly evolving as developments in loco-regional therapies continue to improve. Image-guided radiofrequency (RF) ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection are precluded. Recent refinements in technique have substantially increased the ability of RF ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and non-thermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and the safety profile of TACE compared to conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.

Original languageEnglish (US)
Pages (from-to)107-112
Number of pages6
JournalOncology
Volume78
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Molecular Targeted Therapy
Hepatocellular Carcinoma
Neoplasms
Therapeutics
Pharmaceutical Preparations
Standard of Care
Hot Temperature
Transplantation
Outcome Assessment (Health Care)
Clinical Trials
Safety
Recurrence

Keywords

  • Hepatocellular carcinoma
  • Image-guided ablation
  • Molecular targeted therapies
  • Transarterial chemoembolization

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. / Lencioni, Riccardo.

In: Oncology, Vol. 78, No. SUPPL. 1, 07.2010, p. 107-112.

Research output: Contribution to journalArticle

Lencioni, Riccardo. / Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. In: Oncology. 2010 ; Vol. 78, No. SUPPL. 1. pp. 107-112.
@article{af829f3644054aa9b370b66f806dfacb,
title = "Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies",
abstract = "The treatment of hepatocellular carcinoma (HCC) is rapidly evolving as developments in loco-regional therapies continue to improve. Image-guided radiofrequency (RF) ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection are precluded. Recent refinements in technique have substantially increased the ability of RF ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and non-thermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and the safety profile of TACE compared to conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.",
keywords = "Hepatocellular carcinoma, Image-guided ablation, Molecular targeted therapies, Transarterial chemoembolization",
author = "Riccardo Lencioni",
year = "2010",
month = "7",
doi = "10.1159/000315238",
language = "English (US)",
volume = "78",
pages = "107--112",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies

AU - Lencioni, Riccardo

PY - 2010/7

Y1 - 2010/7

N2 - The treatment of hepatocellular carcinoma (HCC) is rapidly evolving as developments in loco-regional therapies continue to improve. Image-guided radiofrequency (RF) ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection are precluded. Recent refinements in technique have substantially increased the ability of RF ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and non-thermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and the safety profile of TACE compared to conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.

AB - The treatment of hepatocellular carcinoma (HCC) is rapidly evolving as developments in loco-regional therapies continue to improve. Image-guided radiofrequency (RF) ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection are precluded. Recent refinements in technique have substantially increased the ability of RF ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and non-thermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of drug-eluting beads - that enhance drug delivery to the tumor and reduce systemic exposure - appears to improve anticancer activity and the safety profile of TACE compared to conventional regimens. Despite these advances, the long-term outcomes of patients treated with loco-regional therapies remain unsatisfactory because of the high rate of tumor recurrence. The introduction of molecular targeted therapies that inhibit tumor proliferation and angiogenesis has opened new prospects in this regard. Clinical trials focused on combining interventional treatment with systemically active drugs are ongoing. The outcomes of such studies are eagerly awaited, as they have the potential to revolutionize treatment of HCC.

KW - Hepatocellular carcinoma

KW - Image-guided ablation

KW - Molecular targeted therapies

KW - Transarterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=77954494287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954494287&partnerID=8YFLogxK

U2 - 10.1159/000315238

DO - 10.1159/000315238

M3 - Article

C2 - 20616592

AN - SCOPUS:77954494287

VL - 78

SP - 107

EP - 112

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 1

ER -